Amgen AMGN announced that the European Commission (“EC”) has approved Imdylltra (tarlatamab) to treat adults with ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, ...

With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

US biotech major Amgen yesterday announced that the European Commission (EC) has granted marketing authorization for ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

RTX builds a $271B backlog on defense demand and recovering air travel, but tariffs and supply-chain issues cloud growth.

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, ​citing a lack of proven ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...